+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Asia Pacific Plasma Fractionation Market By Product (Immunoglobulins, Albumin, Coagulation factor VIII and Coagulation factor IX), By Sector (Private Sector and Public Sector), By Country, Growth Potential, Industry Analysis Report and Forecast, 2021 - 2027

  • PDF Icon

    Report

  • 68 Pages
  • April 2021
  • Region: Asia Pacific
  • Marqual IT Solutions Pvt. Ltd (KBV Research)
  • ID: 5322584
The Asia Pacific Plasma Fractionation Market is expected to witness market growth of 11.7% CAGR during the forecast period (2021-2027).

Asia-Pacific displays attractive opportunities for leading players operating in the plasma fractionation market. This is due to the existence of governmental bodies that control and manage plasma collection, fractionation, and sales are the primary aspects that are fueling the growth of the plasma fractionation market. Moreover, increasing cases of medical conditions like high fever with thrombocytopenia syndrome (SFTS), hemophilia, and primary & secondary immune deficiencies also propel the development of the market.

Moreover, the surging geriatric population, increasing government support through Medicaid and healthcare policies, and improvements in the healthcare units are some of the determinants for the growth of the plasma fractional market. In addition, key makers are aiming to expand their geographical presence in developing countries of APAC to exploiter the untapped opportunities. This, in turn, is expected to support the growth of the regional plasma fractionation market.

In addition, the plasma fractionation market is expected to witness bright growth prospects due to a surge in the usage of immunoglobulins and alpha-1-antitrypsin in different domains of medicine across the globe. Moreover, untapped growth opportunities in developing countries is expected to present various attractive possibilities for the growth of the global market during the forecast period. On the other hand, the growth of the is expected to be hampered by the huge price of plasma-derived products.

The Immunoglobulins market dominated the Singapore Plasma Fractionation Market by Product in 2020, thereby, achieving a market value of $284.7 Million by 2027. The Albumin market is showcasing a CAGR of 11.8% during (2021 - 2027). Additionally, The Coagulation factor VIII market is expected to witness highest CAGR of 13.9% during (2021 - 2027).

Based on Product, the market is segmented into Immunoglobulins, Albumin, Coagulation factor VIII and Coagulation factor IX. Based on Sector, the market is segmented into Private Sector and Public Sector. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Emergent BioSolutions, Inc., CSL Limited, Grifols S.A., Octapharma AG, Takeda Pharmaceutical Company Limited, Kedrion S.p.A, LFB S.A, Biotest AG (Tiancheng International Investment Limited), Sanquin Blood Supply Foundation, and Bio Products Laboratory Limited.

Scope of the Study

Market Segments covered in the Report:

By Product
  • Immunoglobulins
  • Albumin
  • Coagulation factor VIII
  • Coagulation factor IX

By Sector
  • Private Sector
  • Public Sector

By Country
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific

Companies Profiled
  • Emergent BioSolutions, Inc.
  • CSL Limited
  • Grifols S.A.
  • Octapharma AG
  • Takeda Pharmaceutical Company Limited
  • Kedrion S.p.A
  • LFB S.A
  • Biotest AG (Tiancheng International Investment Limited)
  • Sanquin Blood Supply Foundation
  • Bio Products Laboratory Limited

Unique Offerings from the Publisher
  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Asia Pacific Plasma Fractionation Market, by Product
1.4.2 Asia Pacific Plasma Fractionation Market, by Sector
1.4.3 Asia Pacific Plasma Fractionation Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Asia Pacific Plasma Fractionation Market by Product
3.1 Asia Pacific Immunoglobulins Market by Country
3.2 Asia Pacific Albumin Market by Country
3.3 Asia Pacific Coagulation factor VIII Market by Country
3.4 Asia Pacific Coagulation factor IX Market by Country
Chapter 4. Asia Pacific Plasma Fractionation Market by Sector
4.1 Asia Pacific Private Sector Market by Country
4.2 Asia Pacific Public Sector Market by Country
Chapter 5. Asia Pacific Plasma Fractionation Market by Country
5.1 China Plasma Fractionation Market
5.1.1 China Plasma Fractionation Market by Product
5.1.2 China Plasma Fractionation Market by Sector
5.2 Japan Plasma Fractionation Market
5.2.1 Japan Plasma Fractionation Market by Product
5.2.2 Japan Plasma Fractionation Market by Sector
5.3 India Plasma Fractionation Market
5.3.1 India Plasma Fractionation Market by Product
5.3.2 India Plasma Fractionation Market by Sector
5.4 South Korea Plasma Fractionation Market
5.4.1 South Korea Plasma Fractionation Market by Product
5.4.2 South Korea Plasma Fractionation Market by Sector
5.5 Singapore Plasma Fractionation Market
5.5.1 Singapore Plasma Fractionation Market by Product
5.5.2 Singapore Plasma Fractionation Market by Sector
5.6 Malaysia Plasma Fractionation Market
5.6.1 Malaysia Plasma Fractionation Market by Product
5.6.2 Malaysia Plasma Fractionation Market by Sector
5.7 Rest of Asia Pacific Plasma Fractionation Market
5.7.1 Rest of Asia Pacific Plasma Fractionation Market by Product
5.7.2 Rest of Asia Pacific Plasma Fractionation Market by Sector
Chapter 6. Company Profiles
6.1 Emergent BioSolutions, Inc.
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Regional Analysis
6.1.4 Research & Development Expense
6.2 CSL Limited
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Segmental and Regional Analysis
6.2.4 Research & Development Expense
6.2.5 Recent strategies and developments:
6.2.5.1 Acquisition and Mergers:
6.3 Grifols S.A.
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Segmental and Regional Analysis
6.3.4 Research & Development Expense
6.3.1 Recent strategies and developments:
6.3.1.1 Acquisition and Mergers:
6.4 Octapharma AG
6.4.1 Company Overview
6.4.2 Recent strategies and developments:
6.4.2.1 Approvals:
6.4.2.2 Partnerships, Collaborations, and Agreements:
6.5 Takeda Pharmaceutical Company Limited
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Regional Analysis
6.5.4 Research & Development Expense
6.6 Kedrion S.p.A
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Regional Analysis
6.6.4 Research & Development Expense
6.6.5 Recent strategies and developments:
6.6.5.1 Partnerships, Collaborations, and Agreements:
6.7 LFB S.A.
6.7.1 Company Overview
6.8 Biotest AG (Tiancheng International Investment Limited)
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Segmental and Regional Analysis
6.8.4 Research & Development Expense
6.9 Sanquin Blood Supply Foundation
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Regional Analysis
6.9.4 Research & Development Expense
6.10. Bio Products Laboratory Limited
6.10.1 Company Overview
6.10.2 Recent strategies and developments:
6.10.2.1 Product Launches and Product Expansions:

Companies Mentioned

  • Emergent BioSolutions, Inc.
  • CSL Limited
  • Grifols S.A.
  • Octapharma AG
  • Takeda Pharmaceutical Company Limited
  • Kedrion S.p.A
  • LFB S.A
  • Biotest AG (Tiancheng International Investment Limited)
  • Sanquin Blood Supply Foundation
  • Bio Products Laboratory Limited

Methodology

Loading
LOADING...